REFERENCES


13 “Guide lines for submitting Samples and Analytical Data for Methods Validation”, US Food and Drug Administration, Center for Drugs and Biologics, Department of Health and Human Sciences, 1987.
References


References


38 Joan R, Peter T, Ruben L, Pankaj S; American pharmaceutical review.


42 Hubbard JW, Ganes D, Lim HK, Midha KK; Clinical biochemistry, 19(2) (1986) 107-112.

43 Drayer DW; Clinical pharmacology and therapeutics, 40, (1986) 125.

44 Ariens EJ; Medicinal research reviews, 6, (1986) 451.


References


57 “CDER Guideline on Validation of Chromatographic Methods”, US Food and Drug Administration, Center for Drugs and Biologics, Department of Health and Human Sciences,1994.


59 ICH, Q2B: “Analytical Validation Methodology”, 1996.


References

68 Metha, Akul; Pharma Xchange. Info., 2012.
69 FDA guidance for industry (2000)-analytical procedures and method validation, chemistry, manufacturing, and controls documentation, center for drug evaluation and research and center for biologics evaluation and research.
76 Swartz M, Murphy MB; Am Lab, 37, (2005) 22-27.
81 Formica Jra RN, Lorberb KM, Friedmanb AL, Biaa MJ, Lakkisa F, Smitha JD,


86 Khoschsurur Gholam Ali, (Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Austria), Simultaneous Measurement of Sirolimus and Everolimus in Whole Blood by HPLC with Ultraviolet Detection, Clinical Chemistry, 51 (9): (2005) 1721-1724.


90 Mc Millin GA, Johnson Davis K, Dasgupta A, Analytical performance of a LC-

91 Morgan PE, Brown NW, Tredger TM, A direct method for the measurement of Everolimus and Sirolimus in whole blood by LC-MS/MS using an isotopic everolimus internal standard, Ther Drug Monit 36 (3), (2014) 358-65.

92 Kamberi M, Tran TN, UV-Visible spectroscopy as an alternative to liquid chromatography for determination of everolimus in surfactant containing dissolution Media, 70, (2012) 94-100.

93 Armin Buchwald, Karl Winkler, Thomas Epting, Validation of an LC-MS/MS Method to determine five immune suppressants with deuterated internal standards Including yMPA, BMC clinical pharmacology, 12 (2), (2012) 1472-6904.


98 Plumb,A Jane; Finn,W Paul; Williams,J Robert; Bandara,J Morwenna; Romero, M Rosario; Watkins,J Claire;LaThangue,BNicholas; Brown, Robert, Molecular Cancer Therapeutics, 2(8), (2003) 721-728: PMID 12939461.


107 Jurate Savickiene, Grazina Treigyte, Giedre Valiuliene, Leva Stirbllyte, Ruta Nava Kauskiene, Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone de-Acetylase inhibitor Belinostat in human acute promyelocytic leukemia cells, Anti Cancer Drugs, 25 (8), (2014) 938-49.


116 Rajendra, H., Jani, Kevinkumar, K. M. R., Jain, & Harilal Patel Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in


123 Highleyman L, Elvitegravir “Quad” single-tablet regimen shows continued HIV suppression 48 weeks, HIV and Hepatitis.com.

125 International Conference on Harmonization (ICH) Harmonised Tripartite Validation of Analytical Procedures: Text and Methodology, Q2 (R1), (2005).


127 Raghu Ram Jampala, V. Kiran Kumar, Nemala Appala Raju; Pharmaceutical Methods, 5(1), (2014) 7-13.


141 Djerada Zoubir, Feliu Catherine, Tournois Claire, Vautier Damien, Binet Laurent, Robinet Arnaud, Marty Helene, Gozalo Claire, Lamiable Denis, Millart Herve, Validation of a fast method for quantitative analysis of ELT, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other anti retro viral agents in human plasma samples with a new UPLC-MS/MS technology, Journal of pharmaceutical and biomedical analysis, 86, (2013) 100-11.

142 Azvolinsky, Ph.D., Anna, FDA Approves Ibrutinib for Chronic Lymphocytic Leukemia; Cancer Network, 2014.


146 Sridhar Veeraraghavan, Srikanth Viswanadha, Satish Thappali, Babu Govindarajulu, Swaroopkumar Vakkalanka, Manivannan Rangasamy,
Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study; Journal of Pharmaceutical and Biomedical Analysis, 2014.


168 Chetan A Prajapati, Bhavik S Patel, Development and validation of spectrophotometric method for simultaneous determination of Sildenafil citrate and DAP in their combined dosage formulation, Pharma Tutor, 2(11), (2014) 84-88.


170 Rohith T, Ananda S, Development and validation of HPLC method for the determination of process related impurities in DAP, Int. J. of research in pharmacy and chemistry, 3(1), (2013) 74-82.


177 International Conference on Harmonization specifications, Q6A: Test procedures and acceptance criteria for new drug substances and new drug products chemical substances, 65 (146), (1999) 67488.


179 International Conference on Harmonization guidelines, Q3A validation of analytical procedure: Methodology, 6, (11), (1996).


184 Jia J, Nan F, Liang MZ, Yu Q, Qin YP, Xiang J, China J Hospital Pharmacy, 24 (2010).


195 Azvolinsky, Ph.D., Anna, FDA Approves Ibrutinib for Chronic Lymphocytic Leukemia; Cancer Network, (2014).


References


199 Sridhar Veeraraghavan, Srikant Viswanadha, Satish Thappali, Babu Govindarajulu, Swaroopkumar Vakkalanka, Manivannan Rangasamy, Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study; Journal of Pharmaceutical and Biomedical Analysis, 2014.